Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main objective of this pilot study is to obtain preliminary data on the reactivity of salivary oxytocin during a single LSD intake as part of PAP treatment for anxiety disorders or depression (treatment authorisations granted in advance by the Federal Officie of Public Health for compassionate use of the substance).
There will be no interference with the usual clinical routine in our Service. The protocol is only for taking additional saliva measurements to measure oxytocin levels on the day of treatment.
Participants will be asked to give 4 saliva samples the day of their LSD treatment .In addition they will fill-in self-report questionnaires which are part of the clinical routine
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Lysergic Acid Diethylamide (LSD) | Drug | one single dose of LSD in the context of psychedelic assisted psychotherapy as a part of a clinical routine in our department |
| Measure | Description | Time Frame |
|---|---|---|
| Salivary oxytocin | oxytocin sampled in the saliva | the day of treatment administration (one day) |
| Measure | Description | Time Frame |
|---|---|---|
| Self-reported symptoms of anxiety (STAI-T) | State-Trait Anxiety Inventory (trait), total scores ranging from 20 to 80, higher scores indicating higher anxiety | over 6 months |
| Self-reported depressive symptoms (BDI-II) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Participants will be selected from consecutive patients in the Addiction Department who have received approval from the Federal office of Public healthfor compassionate treatment with LSD as part of Psychedelic assisted psychotherapy for refractory anxiety disorder or depression. ol. Main criteria: Inclusion:
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Geneva University Hospitals | Geneva | Switzerland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003863 | Depression |
| D001008 | Anxiety Disorders |
| ID | Term |
|---|---|
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D008238 | Lysergic Acid Diethylamide |
| ID | Term |
|---|---|
| D008237 | Lysergic Acid |
| D004873 | Ergolines |
| D004876 | Ergot Alkaloids |
| D000470 | Alkaloids |
Not provided
Not provided
Not provided
Not provided
Not provided
Saliva- Salivary oxytocin
Beck Depresion Inventory-II, total scores ranging from 0 to 63, higher scores indicating higher depressive symptoms
| over 6 months |
| Self-reported intensity of mystical experience | Assessed with the self-report Mystical experience Questionnaire (MEQ-30) with total man score ranging from 0 to 5, with higher scores indicating higher intensity of mystical experience | The 1 day of treatment administration |
| Self-reported intensity of Connectedness | Assessed with the self-report Watts Connectedness Scale,total mean score ranging from 0 to 100, with higher scores indicating higher connectedess | The 1 day of treatment administration |
| D006571 |
| Heterocyclic Compounds |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |